Phase 2 study for people with Achondroplasia

Recruiting Phase 2

Sources: ClinicalTrials.gov Checked: 11 October 2026 Not medical advice

This trial at a glance

Status Recruiting
Phase Phase 2
Sponsor Tyra Biosciences, Inc
Registry number NCT06842355
Started 4 March 2025 Today 16 October 2026 Estimated completion 1 January 2030

Where this trial is running

Trial sites and the status recorded for each
SiteCityState or countryStatus at this site
The Children's Hospital at Westmead Westmead NSW Recruiting
Royal Children's Hospital Parkville VIC Recruiting

voxsanity.com.au · trial sites from public registries · registry record synced 11 October 2026 · not medical advice

Who can join

Age 3 Years to 10 Years
Sex Anyone, regardless of sex
Healthy volunteers Not accepted
Enrolment target 92

The official eligibility criteria

Registry text, reproduced exactly. These are the words the trial's sponsor published on ClinicalTrials.gov. They have not been edited, shortened or rewritten, and they are written for researchers rather than for patients.

Inclusion Criteria:

* Aged 3 to 10 years old (inclusive) at the time of consent.

* Informed consent provided by parent(s) or legal guardian(s). As study participants are less than 18 years old, participants are willing and able to provide written assent (where applicable and required).

* Molecular diagnosis of achondroplasia (FGFR3 G380R).

* Radiographically confirmed open growth plates at Screening, as determined by bone age X-ray.

* Able to stand and ambulate independently.

* Able to take oral medication.

* Sentinel Safety Cohort only: aged 5 to 10 years old (inclusive).

* Cohort 1 only: aged 3 to 10 years old (inclusive) and are naive to prior growth accelerating therapy.

* Cohort 2 only: aged 3 to 10 years old (inclusive) and have received prior growth accelerating therapy.

Exclusion Criteria:

* Presence or history of any concurrent disease or condition that would interfere with study participation, safety evaluations, or any uncontrolled or untreated condition that could impact pediatric growth.

* Diagnosis of endocrine condition that alters calcium/phosphate homeostasis.

* Prior limb lengthening surgery or planned or expected to have limb lengthening surgery while enrolled in the study.

* Taking medications that are strong inhibitors or inducers of cytochrome P450 (Cyp) 3A4.

* History or current evidence of corneal or retinal disorder/keratopathy.

* Presence of guided growth hardware/8 plates. Planned or anticipated orthopedic surgeries.

Dates on the record

Started 4 March 2025
Estimated completion 1 January 2030
Registry last updated 1 October 2026
Checked by Voxsanity 11 October 2026

Results, publications and the official record

Sources and dates

  • ClinicalTrials.gov – the record this page reformats
  • ClinicalTrials.gov processing date: 1 October 2026.
  • This page last checked by Voxsanity: 11 October 2026.

Voxsanity reformats data from public registries into this layout. It does not edit, interpret or add to what the registry published.

Not medical advice.

Individual trial records are refreshed on a rolling basis rather than all at once, so a record may be up to several weeks old. Each trial page and trial card shows the date its own record was last synced. Where a record has lagged, its status, sites and enrolment can differ from the current registry state in either direction, so check the registry link on the trial page before acting on them.

Letter for your doctor

A one-page summary of this trial to print or email to your GP. It carries the registry's own record of the trial and its eligibility criteria, and nothing Voxsanity has written about whether it suits you.